Friday, October 14, 2016

pseudoephedrine



soo-doe-e-FED-rin


Commonly used brand name(s)

In the U.S.


  • 12 Hour Cold Maximum Strength

  • Biofed

  • Cenafed

  • Chlor-Trimeton Nasal Decongestant

  • Contac 12-Hour

  • Dimetapp Decongestant

  • Efidac 24 Pseudoephedrine

  • ElixSure Congestion Children's

  • Genaphed

  • Pediacare Decongestant Infants

  • Simply Stuffy

  • Sudafed

Available Dosage Forms:


  • Capsule, Extended Release

  • Tablet, Chewable

  • Tablet, Extended Release

  • Solution

  • Syrup

  • Liquid

  • Tablet

  • Capsule

  • Capsule, Liquid Filled

  • Suspension

Therapeutic Class: Decongestant


Pharmacologic Class: Alpha-Adrenergic Agonist


Uses For pseudoephedrine


Pseudoephedrine is used to relieve nasal or sinus congestion caused by the common cold, sinusitis, and hay fever and other respiratory allergies. It is also used to relieve ear congestion caused by ear inflammation or infection.


Some of these preparations are available only with your doctor's prescription.


Do not give any over-the-counter (OTC) cough and cold medicine to a baby or child under 4 years of age. Using these medicines in very young children might cause serious or possibly life-threatening side effects .


Before Using pseudoephedrine


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For pseudoephedrine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to pseudoephedrine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Pseudoephedrine may be more likely to cause side effects in infants, especially newborn and premature infants, than in older children and adults.


Do not give any over-the-counter (OTC) cough and cold medicine to a baby or child under 4 years of age. Using these medicines in very young children might cause serious or possibly life-threatening side effects .


Geriatric


Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of pseudoephedrine in the elderly with use in other age groups.


Breast Feeding


Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking pseudoephedrine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using pseudoephedrine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Clorgyline

  • Dihydroergotamine

  • Furazolidone

  • Iproniazid

  • Isocarboxazid

  • Linezolid

  • Moclobemide

  • Nialamide

  • Pargyline

  • Phenelzine

  • Procarbazine

  • Rasagiline

  • Selegiline

  • Toloxatone

  • Tranylcypromine

Using pseudoephedrine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Guanethidine

  • Methyldopa

  • Midodrine

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of pseudoephedrine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Type 2 diabetes mellitus—Use of pseudoephedrine may cause an increase in blood glucose levels

  • Enlarged prostate or

  • Glaucoma, or a predisposition to glaucoma or

  • Heart disease or blood vessel disease or

  • High blood pressure—Pseudoephedrine may make the condition worse

  • Overactive thyroid—Use of pseudoephedrine may make the condition worse

Proper Use of pseudoephedrine


For patients taking pseudoephedrine extended-release capsules:


  • Swallow the capsule whole. However, if the capsule is too large to swallow, you may mix the contents of the capsule with jam or jelly and swallow without chewing.

  • Do not crush or chew before swallowing.

For patients taking pseudoephedrine extended-release tablets:


  • Swallow the tablet whole.

  • Do not break, crush, or chew before swallowing.

To help prevent trouble in sleeping, take the last dose of pseudoephedrine for each day a few hours before bedtime. If you have any questions about this, check with your doctor.


Take pseudoephedrine only as directed. Do not take more of it, do not take it more often, and do not take it for a longer period of time than recommended on the label (usually 7 days), unless otherwise directed by your doctor. To do so may increase the chance of side effects.


Dosing


The dose of pseudoephedrine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of pseudoephedrine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For nasal or sinus congestion:
    • For regular (short-acting) oral dosage form (capsules, oral solution, syrup, or tablets):
      • Adults and children 12 years of age and older—60 milligrams (mg) every four to six hours. Do not take more than 240 mg in twenty-four hours.

      • Children 6 to 12 years of age—30 mg every four to six hours. Do not take more than 120 mg in twenty-four hours.

      • Children 4 to 6 years of age—15 mg every four to six hours. Do not take more than 60 mg in twenty-four hours.

      • Children and infants up to 4 years of age—Use is not recommended .


    • For long-acting oral dosage form (extended-release capsules or extended-release tablets):
      • Adults and children 12 years of age and older—120 mg every 12 hours, or 240 mg every 24 hours. Do not take more than 240 mg in 24 hours.

      • Infants and children up to 12 years of age—Use is not recommended .



Missed Dose


If you miss a dose of pseudoephedrine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using pseudoephedrine


If symptoms do not improve within 7 days or if you also have a high fever, check with your doctor since these signs may mean that you have other medical problems.


pseudoephedrine Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor as soon as possible if any of the following side effects occur:


Rare - more common with high doses
  • Convulsions (seizures)

  • hallucinations (seeing, hearing, or feeling things that are not there)

  • irregular or slow heartbeat

  • shortness of breath or troubled breathing

Symptoms of overdose
  • Convulsions (seizures)

  • fast breathing

  • hallucinations (seeing, hearing, or feeling things that are not there)

  • increase in blood pressure

  • irregular heartbeat (continuing)

  • shortness of breath or troubled breathing (severe or continuing)

  • slow or fast heartbeat (severe or continuing)

  • unusual nervousness, restlessness, or excitement

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Nervousness

  • restlessness

  • trouble in sleeping

Less common
  • Difficult or painful urination

  • dizziness or light-headedness

  • fast or pounding heartbeat

  • headache

  • increased sweating

  • nausea or vomiting

  • trembling

  • unusual paleness

  • weakness

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: pseudoephedrine side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More pseudoephedrine resources


  • Pseudoephedrine Side Effects (in more detail)
  • Pseudoephedrine Use in Pregnancy & Breastfeeding
  • Drug Images
  • Pseudoephedrine Drug Interactions
  • Pseudoephedrine Support Group
  • 8 Reviews for Pseudoephedrine - Add your own review/rating


  • Pseudoephedrine MedFacts Consumer Leaflet (Wolters Kluwer)

  • Pseudoephedrine Monograph (AHFS DI)

  • Dimetapp Decongestant Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Drixoral Non-Drowsy Sustained-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

  • Entex Liquid MedFacts Consumer Leaflet (Wolters Kluwer)

  • Entex Consumer Overview

  • Sudafed Consumer Overview

  • Tylenol Simply Stuffy Liquid MedFacts Consumer Leaflet (Wolters Kluwer)



Compare pseudoephedrine with other medications


  • Nasal Congestion

Pentazocine Naloxone





Dosage Form: tablet
Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets

Rx only


Analgesic for Oral Use Only



WARNING: Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is intended for oral use only. Severe, potentially lethal, reactions may result from misuse of Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP by injection either alone or in combination with other substances. (See DRUG ABUSE AND DEPENDENCE section.)




DESCRIPTION


Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets contains pentazocine hydrochloride, USP, equivalent to 50 mg base and is a member of the benzazocine series (also known as the benzomorphan series), and naloxone hydrochloride, USP, equivalent to 0.5 mg base.


Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is an analgesic for oral administration.


Chemically, pentazocine hydrochloride is (2R*,6R*,11R*) - 1,2,3,4,5,6 - Hexahydro - 6,11dimethyl - 3 - (3 - methyl - 2 - butenyl) - 2,6 - methano - 3 - benzazocin - 8 - ol hydrochloride, a white, crystalline substance soluble in acidic aqueous solutions, and has the following structural formula:



C19H27NO . HCl                                                                                                M.W. 321.88


Chemically, naloxone hydrochloride is Morphinan-6-one,4,5-epoxy-3,14-dihydroxy-17-(2propenyl)-, hydrochloride, (5α)-. It is a slightly off-white powder, and is soluble in water and dilute acids, and has the following structural formula:



C19H21NO4 . HCl                                                                                              M.W. 363.84


Inactive Ingredients: Colloidal Silicon Dioxide, Dibasic Calcium Phosphate, D&C Yellow #10, Magnesium Stearate, Microcrystalline Cellulose, Sodium Lauryl Sulfate, Pregelatinized Starch.



CLINICAL PHARMACOLOGY


Pentazocine is a Schedule IV opioid analgesic which when administered orally in a 50 mg dose appears equivalent in analgesic effect to 60 mg of codeine.


Pentazocine weakly antagonizes the analgesic effects of morphine and meperidine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.


Onset of significant analgesia usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer.


Pentazocine is well absorbed from the gastrointestinal tract. Concentrations in plasma coincide closely with the onset, duration, and intensity of analgesia. The time to mean peak concentration in 24 normal volunteers was 1.7 hours (range 0.5 to 4 hours) after oral administration and the mean plasma elimination half-life was 3.6 hours (range 1.5 to 10 hours).


Pentazocine is metabolized in the liver and excreted primarily in the urine. The products of the oxidation of the terminal methyl groups and glucuronide conjugates are excreted by the kidney. Elimination of approximately 60% of the total dose occurs within 24 hours. Pentazocine passes into the fetal circulation.


Naloxone when administered orally at 0.5 mg has no pharmacologic activity. Naloxone hydrochloride administered parenterally at the same dose is an antagonist to pentazocine and a pure antagonist to narcotic analgesics.


Pentazocine hydrochloride and naloxone hydrochloride is a potent analgesic when administered orally. However, the presence of naloxone in Pentazocine hydrochloride and naloxone hydrochloride is intended to prevent the effect of pentazocine if the product is misused by injection.


Studies in animals indicate that the presence of naloxone does not affect pentazocine analgesia when the combination is given orally. If the combination is given by injection the action of pentazocine is neutralized.



INDICATIONS AND USAGE


Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for the relief of moderate to severe pain.


Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for oral use only.



CONTRAINDICATIONS


Pentazocine hydrochloride and naloxone hydrochloride tablets is contraindicated in patients who are hypersensitive to either pentazocine or naloxone.



WARNINGS Drug Dependence


Pentazocine can cause a physical and psychological dependence. (See DRUG ABUSE AND DEPENDENCE.)


Use In Head Injury and Increased Intracranial Pressure


In the presence of head injury, intracranial lesions or a preexisting increase in intracranial pressure, the possible respiratory depressant effects of pentazocine and its potential to elevate cerebrospinal fluid pressure (resulting from vasodilation following CO2 retention) may be markedly increased. Furthermore, pentazocine can produce effects on pupillary response and consciousness, which may obscure neurologic signs of further increases in intracranial pressure in patients with head injuries. In such patients, pentazocine must be used with extreme caution and only if its use is deemed essential.


Interactions with Alcohol and Drugs of Abuse


Pentazocine may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system depression because respiratory depression, hypotension, profound sedation, coma or death may result.


Patients Receiving Narcotics


Pentazocine is a mild narcotic antagonist. Some patients previously given narcotics, including methadone for the daily treatment of narcotic dependence, have experienced withdrawal symptoms after receiving pentazocine.


Respiratory Depression


Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation. Use pentazocine hydrochloride and naloxone hydrochloride with extreme caution in patients with chronic obstructive pulmonary disease or cor pulmonale and in patients having a substantially decreased respiratory reserve (e.g., severe kyphoscoliosis), hypoxia, hypercapnia, or pre-existing respiratory depression. Alternative non-opioid analgesics should be considered, and pentazocine hydrochloride and naloxone hydrochloride should be employed only under careful medical supervision at the lowest effective dose in such patients.


Acute CNS Manifestations


Patients receiving therapeutic doses of pentazocine hydrochloride and naloxone hydrochloride have experienced hallucinations (usually visual), disorientation, and confusion which have cleared spontaneously within a period of hours. The mechanism of this reaction is not known. Such patients should be very closely observed and vital signs checked. If the drug is reinstituted, it should be done with caution since these acute CNS manifestations may recur.



PRECAUTIONS



Drug Abuse and Dependence


Pentazocine hydrochloride and naloxone hydrochloride tablets are Schedule IV controlled substance.


Abuse and addiction are separate and distinct from physical dependence and tolerance. Abuse is characterized by misuse of a drug for non-medical purposes, often in combination with other psychoactive substances. Addiction is a disease of repeated drug abuse. Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. Addiction is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease, utilizing a multidisciplinary approach, but relapse is common. Physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, and/or administration of an antagonist. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug’s effects over time. Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.


Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of addiction and is characterized by misuse of the drug for non-medical purposes, and often in combination with other psychoactive substances.


There have been some reports of dependence and of withdrawal symptoms with pentazocine hydrochloride and naloxone hydrochloride. Patients with a history of drug dependence should be under close supervision while receiving Pentazocine hydrochloride and naloxone hydrochloride. There have been rare reports of possible abstinence syndromes in newborns after prolonged use of pentazocine hydrochloride and naloxone hydrochloride during pregnancy.


There have been reports of development of addiction and physical dependence in patients receiving parenteral pentazocine. People with a history of drug abuse or alcohol abuse may have a higher chance of becoming addicted to opioid medicines.


Abrupt dose cessation or rapid dose reduction following the extended use of parenteral pentazocine has resulted in withdrawal symptoms such as abdominal cramps, nausea, vomiting, elevated temperature, chills, rhinorrhea, restlessness, anxiety, or lacrimation. In general opioid therapy should not be abruptly discontinued. When the patient no longer requires treatment with pentazocine hydrochloride and naloxone hydrochloride, the drug should be tapered gradually to prevent signs and symptoms of withdrawal in patients who have been receiving opioids for an extended period of time and might have become physically dependent.


In prescribing pentazocine hydrochloride and naloxone hydrochloride for chronic use, the physician should take under consideration that proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to identify and decrease misuse and abuse of opioid drugs.


The amount of naloxone present in pentazocine hydrochloride and naloxone hydrochloride (0.5 mg per tablet) has no action when taken orally and will not interfere with the pharmacologic action of pentazocine. However, this amount of naloxone given by injection has profound antagonistic action to narcotic analgesics.


Severe, even lethal, consequences may result from misuse of tablets by injection either alone or in combination with other substances, such as pulmonary emboli, vascular occlusion, ulceration and abscesses, and withdrawal symptoms in narcotic dependent individuals.


CNS Effect


Caution should be used when pentazocine hydrochloride and naloxone hydrochloride is administered to patients prone to seizures; seizures have occurred in a few such patients in association with the use of pentazocine though no cause and effect relationship has been established.


Porphyria


Particular caution should be exercised in administering pentazocine to patients with porphyria since it may provoke an acute attack in susceptible individuals.


Cardiovascular Disease


Pentazocine can elevate blood pressure, possibly through the release of endogenous catecholamines. Particular caution should be exercised in conditions where alterations in vascular resistance and blood pressure might be particularly undesirable, such as in the acute phase of myocardial infarction.


Pentazocine hydrochloride and naloxone hydrochloride should be used with caution in patients with myocardial infarction who have nausea or vomiting.


Impaired Renal or Hepatic Function


Decreased metabolism of pentazocine by the liver in extensive liver disease may predispose to accentuation of side effects. Although laboratory tests have not indicated that pentazocine causes or increases renal or hepatic impairment, the drug should be administered with caution to patients with such impairment.


Other


Caution should also be observed when administering pentazocine hydrochloride and naloxone hydrochloride in patients with hypothyroidism, adrenocortical insufficiency, prostate hypertrophy, inflammatory or obstructive bowel disease, acute abdominal syndromes of unknown etiology, cholecystitis, pancreatitis, or acute alcohol intoxication and delirium tremens.


Biliary Surgery


Narcotic drug products are generally considered to elevate biliary tract pressure for varying periods following their administration. Some evidence suggests that pentazocine may differ from other marketed narcotics in this respect (i.e., it causes little or no elevation in biliary tract pressures). The clinical significance of these findings, however, is not yet known.



Information for Patients


  • Patients receiving pentazocine hydrochloride and naloxone hydrochloride should be given the following instructions by the physician:

  • Patients should be advised that pentazocine hydrochloride and naloxone hydrochloride is a narcotic pain reliever, and should be taken only as directed.

  • The dose of pentazocine hydrochloride and naloxone hydrochloride should not be adjusted without consulting with a physician or other healthcare professional.

  • Patients should be advised that pentazocine hydrochloride and naloxone hydrochloride may cause drowsiness, dizziness, or lightheadedness and may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating machinery). Patients started on pentazocine hydrochloride and naloxone hydrochloride or patients whose dose has been adjusted should refrain from any potentially dangerous activity until it is established that they are not adversely affected.

  • Pentazocine hydrochloride and naloxone hydrochloride will add to the effect of alcohol and other CNS depressants (such as antihistamines, sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, and monoamine oxidase [MAO]inhibitors).

  • Patients should not combine pentazocine hydrochloride and naloxone hydrochloride with alcohol or other central nervous system depressants (sleep aids, tranquilizers) except by the orders of the prescribing physician, because dangerous additive effects may occur, resulting in serious injury or death.

  • Women of childbearing potential who become or are planning to become pregnant should consult a physician prior to initiating or continuing therapy with pentazocine hydrochloride and naloxone hydrochloride.

  • Safe use in pregnancy has not been established. Prolonged use of opioid analgesics during pregnancy may cause neonatal physical dependence, and neonatal withdrawal may occur.

  • If patients have been receiving treatment with pentazocine hydrochloride and naloxone hydrochloride for more than a few weeks and cessation of therapy is indicated, they should be counseled on the importance of safely tapering the dose and that abruptly discontinuing the medication could precipitate withdrawal symptoms. The physician should provide a dose schedule to accomplish a gradual discontinuation of the medication.

  • Patients should be advised that pentazocine hydrochloride and naloxone hydrochloride is a potential drug of abuse. They should protect it from theft. It should never be given to anyone other than the individual for whom it was prescribed.

  • Patients should be instructed to keep pentazocine hydrochloride and naloxone hydrochloride in a secure place out of the reach of children. When Pentazocine hydrochloride and naloxone hydrochloride is no longer needed, please consult your pharmacist for proper disposal instructions.

  • As with other opioids, patients taking pentazocine hydrochloride and naloxone hydrochloride should be advised of the potential for severe constipation; appropriate laxatives and/or stool softeners as well as other appropriate treatments should be initiated from the onset of opioid therapy.

  • Patients should be advised of the most common adverse events that may occur while taking pentazocine hydrochloride and naloxone hydrochloride: constipation, nausea, somnolence, lightheadedness, dizziness, sedation, vomiting, and sweating.


Drug Interactions


CNS Depressants


Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma. Use morphine sulfate with caution and in reduced dosages in patients taking these agents.


Opioid Agonist Analgesics


Pentazocine hydrochloride and naloxone hydrochloride can antagonize the effects of a pure opioid agonist analgesic and/or may precipitate withdrawal symptoms.


Monoamine Oxidase Inhibitors (MAOIs)


Concomitant use of monoamine oxidase inhibitors (MAOIs) with pentazocine hydrochloride and naloxone hydrochloride may cause CNS excitation and hypertension through their respective effects on catecholamines. Caution should therefore be observed in administering pentazocine hydrochloride and naloxone hydrochloride to patients who are currently receiving MAOIs or who have received them within the preceding 14 days.


Anticholinergics


Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.


Tobacco


Smoking tobacco could enhance the metabolic clearance rate of pentazocine reducing the clinical effectiveness of a standard dose of pentazocine.



Carcinogenesis, Mutagenesis, Impairment of Fertility


No long-term studies in animals to test for carcinogenesis have been performed with the components of pentazocine hydrochloride and naloxone hydrochloride.


Studies to evaluate the mutagenic potential of the components of pentazocine hydrochloride and naloxone hydrochloride have not been conducted.


Pentazocine, when administered orally or parenterally, had no adverse effect on either the reproductive capabilities or the course of pregnancy in rabbits and rats. Embryotoxic effects on the fetuses were not shown.


The daily administration of 4 mg/kg to 20 mg/kg pentazocine subcutaneously to female rats during a 14 day pre-mating period and until the 13th day of pregnancy did not have any adverse effects on the fertility rate.



Pregnancy


Teratogenic Effects

Pregnancy Category C


There are no adequate and well-controlled studies in pregnant women. Pentazocine hydrochloride and naloxone hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.


In a published report, a single dose of pentazocine administered to pregnant hamsters on gestation day 8 increased the incidence of exencephaly and cranioschisis at a dose of 196 mg/kg, SC (0.4-times the maximum daily human dose of pentazocine via 12 tablets on a mg/m2 basis).


Animal reproduction studies testing the combination of pentazocine and naloxone during organogenesis have been completed in rats and rabbits. In rats, a pentazocine:naloxone dose of 64 mg/kg:0.64 mg/kg via oral gavage increased the incidences of resorptions and extra ribs (0.2-times the maximum daily human dose of pentazocine via 12 tablets on a mg/m2 basis). There were no clear treatment related effects in rabbits treated with a pentazocine:naloxone dose of up to 64 mg/kg:0.64 mg/kg via oral gavage (0.3-times the maximum daily human dose of pentazocine via 12 tablets on a mg/m2 basis).


Nonteratogenic Effects

There has been no experience in this regard with pentazocine hydrochloride and naloxone hydrochloride. However, there have been rare reports of possible abstinence syndromes in newborns after prolonged use of pentazocine during pregnancy.



Labor and Delivery


Patients receiving pentazocine during labor have experienced no adverse effects other than those that occur with commonly used analgesics. However, pentazocine can cross the placental barrier and cause central nervous system depression in the newborn and, if used regularly throughout pregnancy, may lead to symptoms of withdrawal in the newborn. pentazocine hydrochloride and naloxone hydrochloride should be used with caution in women delivering premature infants. The effect of pentazocine hydrochloride and naloxone hydrochloride on the mother and fetus, the duration of labor or delivery, the possibility that forceps delivery or other intervention or resuscitation of the newborn may be necessary, or the effect of pentazocine hydrochloride and naloxone hydrochloride on the later growth, development, and functional maturation of the child are unknown at the present time.



Nursing Mothers


Pentazocine is excreted in human milk. Caution should be exercised when pentazocine hydrochloride and naloxone hydrochloride is administered to a nursing woman.



Pediatric Use


Safety and effectiveness in pediatric patients below the age of 12 years have not been established.



Geriatric Use


Controlled clinical studies of pentazocine hydrochloride and naloxone hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses or effectiveness in analgesic activity between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.



ADVERSE REACTIONS


Cardiovascular. Hypertension, hypotension, circulatory depression, tachycardia, syncope.


Respiratory. Rarely, respiratory depression.


Acute CNS Manifestations. Hallucinations (usually visual), disorientation, and confusion .


Other CNS Effects. Grand mal convulsions, increase in intracranial pressure, dizziness, lightheadedness, hallucinations, sedation, euphoria, headache, confusion, disorientation; infrequently weakness, disturbed dreams, insomnia, syncope, and depression; and rarely tremor, irritability, excitement, tinnitus.


Autonomic. Sweating; infrequently flushing; and rarely chills.


Gastrointestinal. Nausea, vomiting, constipation, diarrhea, anorexia, dry mouth, biliary tract spasm, and rarely abdominal distress.


Allergic. Edema of the face; anaphylactic shock; dermatitis, including pruritus; flushed skin, including plethora; infrequently rash, and rarely urticaria.


Ophthalmic. Visual blurring and focusing difficulty, miosis.


Hematologic. Depression of white blood cells (especially granulocytes), with rare cases of agranulocytosis, which is usually reversible, moderate transient eosinophilia.


Dependence and Withdrawal Symptoms. (See WARNINGS, PRECAUTIONS, and DRUG ABUSE AND DEPENDENCE Sections).


Other. Urinary retention, paresthesia, serious skin reactions, including erythema multiforme, Stevens-Johnson syndrome toxic epidermal necrolysis, and alterations in rate or strength of uterine contractions during labor.



OVERDOSAGE


Manifestations


For pentazocine alone in single doses above 60 mg there have been reports of the occurrence of nalorphine-like psychotomimetic effects such as anxiety, nightmares, strange thoughts, and hallucinations. Somnolence, marked respiratory depression associated with hypertension and tachycardia have also resulted as have seizures, hypotension, dizziness, nausea, vomiting, lethargy, and paresthesias. The respiratory depression is antagonized by naloxone (see Treatment). Circulatory failure and deepening coma may occur in more severe cases, particularly in patients who have also ingested other CNS depressants such as alcohol, sedative/hypnotics, or antihistamines.



Treatment


Adequate measures to maintain ventilation and general circulatory support should be employed. Assisted or controlled ventilation, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Consideration should be given to gastric lavage and gastric aspiration. For respiratory depression due to overdosage or unusual sensitivity to pentazocine, parenteral naloxone is a specific and effective antagonist. Initial doses of 0.4 to 2.0 mg of naloxone are recommended, repeated at 2-3 minute intervals, if needed, up to a total of 10 mg. Anti-convulsant therapy may be necessary.



DOSAGE AND ADMINISTRATION


Adults


The usual initial adult dose is 1 tablet every three or four hours. This may be increased to 2 tablets when needed. Total daily dosage should not exceed 12 tablets.


Discontinuation


Due to the potential for withdrawal symptoms associated with abrupt discontinuation, consideration should be given to tapering patients off pentazocine hydrochloride and naloxone hydrochloride after prolonged periods of treatment with pentazocine hydrochloride and naloxone hydrochloride (See PRECAUTIONS, Drug Abuse and Dependence).



HOW SUPPLIED


Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is available as light yellow, capsule shaped tablet debossed “NL” on left side and “680” on the right side of the bisect and plain on the other side. Each tablet contains pentazocine hydrochloride equivalent to 50 mg base and naloxone hydrochloride equivalent to 0.5 mg base.


Bottles of 100 (NDC 43386-680-01).


Store at 20° C -25° C (68° - 77° F); See USP Controlled Room Temperature.


Manufactured by:

Novel Laboratories, Inc.

Somerset, NJ 08873


Distributed by:

GAVIS Pharmaceuticals, LLC

Somerset, NJ 08873


GIN-680-01

Rev: 04/2011



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL










PENTAZOCINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE 
pentazocine hydrochloride and naloxone hydrochloride  tablet










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)43386-680
Route of AdministrationORALDEA ScheduleCIV    











Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
PENTAZOCINE HYDROCHLORIDE (PENTAZOCINE)PENTAZOCINE HYDROCHLORIDE50 mg
NALOXONE HYDROCHLORIDE (NALOXONE)NALOXONE HYDROCHLORIDE0.5 mg


















Inactive Ingredients
Ingredient NameStrength
SILICON DIOXIDE 
D&C YELLOW NO. 10 
DIBASIC CALCIUM PHOSPHATE DIHYDRATE 
SODIUM LAURYL SULFATE 
MAGNESIUM STEARATE 
CELLULOSE, MICROCRYSTALLINE 
STARCH, CORN 


















Product Characteristics
ColorYELLOWScorescore with uneven pieces
ShapeCAPSULESize13mm
FlavorImprint CodeNL;680
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
143386-680-01100 TABLET In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA07573505/11/2011


Labeler - GAVIS Pharmaceuticals, LLC (829838551)









Establishment
NameAddressID/FEIOperations
Novel Laboratories, Inc.793518643MANUFACTURE
Revised: 06/2011GAVIS Pharmaceuticals, LLC

More Pentazocine Naloxone resources


  • Pentazocine Naloxone Side Effects (in more detail)
  • Pentazocine Naloxone Dosage
  • Pentazocine Naloxone Use in Pregnancy & Breastfeeding
  • Drug Images
  • Pentazocine Naloxone Drug Interactions
  • Pentazocine Naloxone Support Group
  • 12 Reviews for Pentazocine Naloxone - Add your own review/rating


Compare Pentazocine Naloxone with other medications


  • Pain

Psorcon


Generic Name: Diflorasone Diacetate
Class: Anti-inflammatory Agents
ATC Class: D07AC10
VA Class: DE200
Chemical Name: 6α,9-Difluoro-11β, 17, 21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate
Molecular Formula: C26H32F2O7
CAS Number: 33564-31-7

Introduction

A synthetic fluorinated corticosteroid.a


Uses for Psorcon


Corticosteroid-responsive Dermatoses


Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.a c e f g h


Generally most effective in acute or chronic dermatoses (e.g., seborrheic or atopic dermatitis, localized neurodermatitis, anogenital pruritus, psoriasis, late phase of allergic contact dermatitis, inflammatory phase of xerosis).b


Topical therapy generally preferred over systemic therapy; fewer associated adverse systemic effects.b


Topical therapy generally only controls manifestations of dermatoses; eliminate cause if possible.b


Topical efficacy may be increased by using a higher concentration or occlusive dressing therapy. (See Administration with Occlusive Dressing under Dosage and Administration.)b


Response may vary from one topical corticosteroid preparation to another.b


Anti-inflammatory activity may vary considerably depending on the vehicle, drug concentration, site of application, disease, and individual patient.b


Manufacturers state that cream should not be used for the treatment of rosacea or perioral dermatitis.e g


Diflorasone 0.05% cream and ointment are considered to have high-range potency; emollient base increases the potency.b e


Psorcon Dosage and Administration


General



  • Consider location of the lesion and the condition being treated when choosing a dosage form.b




  • Creams are suitable for most dermatoses, but ointments may also provide some occlusion and are usually used for the treatment of dry, scaly lesions.b




  • Formulation affects percutaneous penetration and subsequent activity; extemporaneous preparation or dilution of commercially available products with another vehicle may decrease effectiveness.b




  • Patients applying a topical corticosteroid to a large surface area and/or to areas under occlusion should be evaluated periodically for evidence of hypothalamic-pituitary-adrenal (HPA)-axis suppression by appropriate endocrine testing (e.g., ACTH stimulation, plasma cortisol, urinary free cortisol). b f g (See Hypothalamic-Pituitary-Adrenal Axis Suppression and also Systemic Effects, under Cautions.)



Administration


Topical Administration


For dermatologic use only; avoid contact with eyes.c e g


Apply creams and ointments topically to the skin or scalp.c e


Do not use cream on face, groin, or axillae.e g


The area of skin to be treated may be thoroughly cleansed before topical application to reduce the risk of infection; however, some clinicians believe that, unless an occlusive dressing is used, cleansing of the treated area is unnecessary and may be irritating.b


Apply cream or ointment sparingly in a thin film and rub gently into the affected area.c f h


After a favorable response is achieved, frequency of application or concentration (strength) may be decreased to the minimum necessary to maintain control and to avoid relapse; discontinue if possible.b


Administration with Occlusive Dressing

Occlusive dressings may be used for severe or resistant dermatoses.c (See Occlusive Dressings under Cautions.)


Soak or wash the affected area to remove scales; apply a thin film of cream or ointment; rub gently into the lesion; and apply another thin film.b Cover affected area with a thin, pliable plastic film and seal it to adjacent normal skin with adhesive tape or hold in place with a gauze or elastic bandage.b


If affected area is moist, incompletely seal the edges of the plastic film or puncture the film to allow excess moisture to escape.b For added moisture in dry lesions, apply cream or ointment and cover with a dampened cloth before the plastic film is applied or briefly soak the affected area in water before application of the drug and plastic film.b


Thin polyethylene gloves may be used on the hands and fingers, plastic garment bags may be used on the trunk or buttocks, a tight shower cap may be used for the scalp, or whole-body suits may be used instead of plastic film to provide occlusion.b


Frequency of occlusive dressing changes depends on the condition being treated; cleansing of the skin and reapplication of the corticosteroid are essential at each dressing change.b


Occlusive dressing is usually left in place for 12–24 hours and therapy is repeated as needed.b Although occlusive dressing may be left in place for 3–4 days at a time in resistant conditions, most clinicians recommend intermittent use of occlusive dressings for 12 hours daily to reduce the risk of adverse effects (particularly infection) and systemic absorption and for greater convenience.b


The drug and an occlusive dressing may be used at night, and the drug or a bland emollient may be used without an occlusive dressing during the day.b


In patients with extensive lesions, sequential occlusion of only one portion of the body at a time may be preferable to whole-body occlusion.b (See Occlusive Dressings under Cautions.)


Dosage


Pediatric Patients


Administer the least amount of topical preparations that provide effective therapy.b c (See Pediatric Use under Cautions.)


Corticosteroid-responsive Dermatoses

Topical

Apply ointment sparingly 1–3 times daily.c


Adults


Corticosteroid-responsive Dermatoses

Topical

Apply cream sparingly twice daily.e


Apply ointment or emollient cream sparingly 1–3 times daily.c f


Apply emollient ointment sparingly 1–4 times daily.h


Special Populations


No special population dosage recommendations at this time.c e f g h


Cautions for Psorcon


Contraindications



  • Known hypersensitivity to diflorasone or any ingredient in the formulation.c e f g h



Warnings/Precautions


Sensitivity Reactions


Allergic contact dermatitis may manifest as failure to heal rather than irritation as occurs with other topical preparations that do not contain corticosteroids; confirm with diagnostic patch testing.b e g


General Precautions


Hypothalamic-Pituitary-Adrenal Axis Suppression

Topically applied corticosteroids can be absorbed in sufficient amounts to reversibly suppress the HPA axis.b c e g


Manufacturers state cream has greater ability to produce adrenal suppression than ointment.e g


Perform periodic HPA-axis evaluation by appropriate testing (e.g., ACTH stimulation,b c e f g h morning plasma cortisol,b e g urinary free cortisolb c e f g h ), especially in patients applying a topical corticosteroid to a large surface area or to areas under occlusion.b f h


If HPA-axis suppression occurs, withdraw the drug, reduce the frequency of application, and/or substitute a less potent corticosteroid.b c e f g h


HPA-axis function recovery generally is prompt and complete following drug discontinuance.b c e f g h


Rarely, glucocorticosteroid insufficiency may require systemic corticosteroid therapy.b c e f g h


Systemic Effects

Systemic absorption following topical administration may result in manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.b c e f g h


Adverse systemic effects may occur when corticosteroids are used on large areas of the body, for prolonged periods of time, with an occlusive dressing, and/or concurrently with other corticosteroid-containing preparations.b c f h


Infants and children may be more susceptible to adverse systemic effects.c e f g h (See Pediatric Use under Cautions.)


Local Effects

Possible adverse local reactions (e.g., burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria); may occur more frequently with the use of occlusive dressings, especially with prolonged therapy.b


Prolonged use of topical corticosteroids may cause atrophy of the epidermis and subcutaneous tissue;b these effects are most likely to occur (even with short-term use) in intertriginous (e.g., axilla, groin), flexor, and facial areas.b


If irritation occurs, discontinue drug and institute appropriate therapy.b c e f g h


Skin Infection

If concurrent skin infection is present or develops, initiate appropriate anti-infective therapy.b c e f g h If infection does not respond promptly, discontinue topical corticosteroid therapy until the infection has been controlled.b c e f g h


When topical corticosteroids and topical anti-infectives are used concomitantly, consider that the corticosteroid may mask clinical signs of bacterial, fungal, or viral infections; prevent recognition of ineffectiveness of the anti-infective; or suppress hypersensitivity reactions to ingredients in the formulation.b In addition, consider the cautions, precautions, and contraindications associated with the anti-infective.b (See Occlusive Dressings under Cautions.)


Some manufacturers state that topical corticosteroids are contraindicated in patients with tuberculosis of the skin, dermatologic fungal infections, and cutaneous or systemic viral infection (including vaccinia and varicella and herpes simplex of the eye or adjacent skin).b However, most clinicians believe topical corticosteroids can be used with caution if the infection is treated.b


Occlusive Dressings

Adverse systemic corticosteroid effects may occur with use of occlusive dressings on large areas of the body and for prolonged periods of time; monitor accordingly.b (See Hypothalamic-Pituitary-Adrenal Axis Suppression and also Systemic Effects, under Cautions.)


Adverse local reactions may occur more frequently with the use of occlusive dressings, especially with prolonged therapy.b (See Local Effects under Cautions.)


Do not use occlusive dressings on weeping or exudative lesions.b


Do not use occlusive dressings in patients with primary skin infection.b


Remove occlusive dressings covering large areas if body temperature increases; thermal homeostasis may be impaired.b


If infection develops, discontinue use of occlusive dressings and institute appropriate antimicrobial therapy.c f h (See Skin Infection under Cautions.)


Use plastic occlusive material with care to avoid the risk of suffocation.b


Specific Populations


Pregnancy

Category C.c e f g h


Lactation

Not known whether topical diflorasone is distributed into milk.c e f g h Caution advised if topical diflorasone is used.c e f g h


Pediatric Use

Safety and efficacy of cream, emollient cream, or emollient ointment not established.e f g h


Tight-fitting diapers or plastic pants should not be used on a child being treated with diflorasone in the diaper area, since they may constitute occlusive dressings.b c f h


Children are more susceptible to topical corticosteroid-induced HPA-axis suppression and Cushing's syndrome than mature individuals because of a greater skin surface area-to-body weight ratio,c e f g h especially when topical corticosteroids are applied to >20% of body surface area.i The risk of adrenal suppression appears to increase with decreasing age.b (See Systemic Effects under Cautions.)


Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol concentrations, and lack of response to corticotropin (ACTH) stimulation.b c e f g h


Children also are at greater risk of glucocorticoid insufficiency during and/or after withdrawal of treatment.b c f h


Intracranial hypertension has occurred in children; manifestations include bulging fontanelles, headaches, and bilateral papilledema.b c f h


Striae have been reported in children treated inappropriately with topical corticosteroids.b h


Topical corticosteroid therapy in children should be limited to the minimum amount necessary for therapeutic efficacy; chronic topical corticosteroid therapy may interfere with growth and development.b c


Common Adverse Effects


Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infections, skin atrophy, striae, miliaria.c e f g h


Interactions for Psorcon


Specific Drugs and Laboratory Tests







Drug or Test



Interaction



Nitroblue-tetrazolium test for bacterial infection



Concurrent use of corticosteroids reportedly may result in false-negative resultsb


Psorcon Pharmacokinetics


Absorption


Bioavailability


Topically applied diflorasone can be absorbed through normal intact skin.b c e f g h


Percutaneous penetration of corticosteroids following topical application to the skin varies among individuals and may be increased by occlusive dressings, high corticosteroid concentrations, and certain vehicles.b f h


Only minimal amounts of topical corticosteroid reach the dermis and subsequently the systemic circulation after application to most normal skin areas; more absorption occurs from the scrotum, axilla, eyelid, face, and scalp than from the forearm, knee, elbow, palm, and sole.b


Absorption is markedly increased by loss of the skin’s keratin layer and by inflammation and/or diseases of the epidermal barrier (e.g., psoriasis, eczema).b c e f g h


Distribution


Extent


Not known whether topical diflorasone is distributed into milk.c g


Elimination


Metabolism


Once absorbed through the skin, topically applied corticosteroids are metabolized primarily in the liver.b c f h


Elimination Route


Topical corticosteroids and metabolites are excreted by the kidneys and, to a lesser extent, in bile.b c f h


Stability


Storage


Topical


Cream

≤25°C;e g keep tightly closed.g


Ointment

15–30°C; keep tightly closed.c


Emollient Cream and Ointment

20–25°C.f h


ActionsActions



  • Precise mechanism of action for topical anti-inflammatory activity is unknown;c e f g h therapeutic benefit in the management of corticosteroid-responsive dermatoses mediated primarily through anti-inflammatory, antipruritic, and vasoconstrictive actions.b c e f g h




  • Anti-inflammatory effects may occur through induction of phospholipase A2 inhibitory proteins (lipocortins); decreased arachidonic acid release from membrane phospholipids.e g Decreased arachidonic acid precursors may downregulate biosynthesis of potent inflammatory mediators (e.g., prostaglandins, leukotrienes).e g




  • Decreases inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation; and possibly by other mechanisms as yet unknown.b



Advice to Patients



  • Importance of using only as directed, only for the disorder for which it was prescribed, and for no longer than prescribed; avoid contact with the eyes and only apply externally as directed.c e f g h (See Topical Administration under Dosage and Administration.)




  • Importance of informing patients that treated areas of the skin should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by a clinician.c e f g h




  • Importance of reporting any local adverse reactions, especially those occurring under occlusive bandage, to a clinician.b c e f g h




  • Importance of informing parents of children not to use diapers or plastic pants on children being treated in the diaper area as these garments may act as occlusive dressings.c f h




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.c




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.c e f g h




  • Importance of advising patients of other important precautionary information. (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

































Diflorasone Diacetate

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Topical



Cream



0.05%*



Diflorasone Diacetate Cream (with propylene glycol)



Fougera, Taro



Psorcon (with propylene glycol)



Dermik



Psorcon E Emollient Cream (with propylene glycol; in a hydrophilic cream base)



Dermik



Ointment



0.05%*



Diflorasone Diacetate Ointment (with propylene glycol)



Fougera, Taro



Psorcon E Emollient Ointment (with propylene glycol)



Dermik


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


ApexiCon E 0.05% Cream (PHARMADERM): 60/$240 or 180/$709.96


Diflorasone Diacetate 0.05% Cream (FOUGERA): 15/$35.99 or 45/$95.97


Diflorasone Diacetate 0.05% Cream (FOUGERA): 60/$89.99 or 180/$249.98


Diflorasone Diacetate 0.05% Ointment (TARO): 15/$30.99 or 45/$91.98


Diflorasone Diacetate 0.05% Ointment (TARO): 60/$67.99 or 180/$196.98


Diflorasone Diacetate 0.05% Ointment (TARO): 30/$37.99 or 90/$105.97



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions January 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



a. AHFS drug information 2007. McEvoy GK, ed. Diflorasone. Bethesda, MD: American Society of Health-Systems Pharmacists; 2007: 3530.



b. AHFS drug information 2007 McEvoy GK, ed. Topical corticosteroids general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2005:3423–5.



c. E. Fougera & Co. Diflorasone diacetate ointment USP, 0.05% prescribing information. Mellville, NY; 1998 Oct.



e. Dermik Laboratories, Inc. Psorcon (diflorasone diacetate) cream prescribing information. Berwyn, PA; 2002 Mar.



f. Dermik Laboratories, Inc. Psorcon E (diflorasone diacetate) 0.05% emollient cream prescribing information. Berwyn, PA; 2001 Dec.



g. E. Fougera & Co. Diflorasone diacetate cream USP, 0.05% prescribing information. Melville, NY; 1998 Feb.



h. Dermik Laboratories, Inc. Psorcon E (diflorasone diacetate) 0.05% emollient ointment prescribing information. Berwyn, PA; 2001 Dec.



i. Connetics Corporation. Verdeso (desonide) aerosol, foam prescribing information. Palo Alto, CA; 2006 Oct.



More Psorcon resources


  • Psorcon Side Effects (in more detail)
  • Psorcon Use in Pregnancy & Breastfeeding
  • Psorcon Drug Interactions
  • Psorcon Support Group
  • 0 Reviews for Psorcon - Add your own review/rating


  • Psorcon Advanced Consumer (Micromedex) - Includes Dosage Information

  • ApexiCon Concise Consumer Information (Cerner Multum)

  • Apexicon Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Apexicon Prescribing Information (FDA)

  • Apexicon E Prescribing Information (FDA)

  • Florone Prescribing Information (FDA)

  • psorcon Prescribing Information (FDA)



Compare Psorcon with other medications


  • Atopic Dermatitis
  • Eczema
  • Psoriasis
  • Skin Rash
  • Urticaria

Thursday, October 13, 2016

Provenge


Pronunciation: SI-pu-LOO-sel-TEE
Generic Name: Sipuleucel-T
Brand Name: Provenge


Provenge is used for:

Treating a certain type of advanced prostate cancer. It may also be used for other conditions as determined by your doctor.


Provenge is an autologous blood cell and immune cell activator combination. It works by targeting certain cancer cells in your prostate and increasing the immune response directed at them, which stops the growth and reproduction of the prostate cancer.


Do NOT use Provenge if:


  • you are allergic to any ingredient in Provenge

Contact your doctor or health care provider right away if any of these apply to you.



Before using Provenge:


Some medical conditions may interact with Provenge. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of heart or lung problems, or a stroke

Some MEDICINES MAY INTERACT with Provenge. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Chemotherapy medicines (eg, cisplatin) or immunosuppressive agents (eg, prednisone) because they may decrease Provenge's effectiveness

This may not be a complete list of all interactions that may occur. Ask your health care provider if Provenge may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Provenge:


Use Provenge as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • An extra patient leaflet is available with Provenge. Talk to your pharmacist if you have questions about this information.

  • Provenge is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Provenge at home, a health care provider will teach you how to use it. Be sure you understand how to use Provenge. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.

  • Your doctor may prescribe other medicines, including acetaminophen and an antihistamine (eg, diphenhydramine) for you to take before you use Provenge. This will help to decrease the risk of infusion-related side effects. Be sure to take these medicines exactly as prescribed by your doctor. If you miss a dose of these medicines or you do not take them exactly as prescribed, tell your doctor or nurse before your treatment with Provenge.

  • Provenge should be slightly cloudy and a cream-to-pink color. Gently mix Provenge before using. Do not use Provenge if it contains particles or clumps after mixing, it is discolored, or if the container leaks or is cracked or damaged.

  • If you miss a dose of Provenge, contact your doctor right away.

Ask your health care provider any questions you may have about how to use Provenge.



Important safety information:


  • Provenge may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Provenge with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Provenge is made from your own immune cells. You will be required to undergo a collection procedure (leukapheresis) where immune cells (eg, white blood cells) are removed from your blood about 3 days before each scheduled infusion of Provenge. These cells will be combined with a protein to make them ready for your infusion. Each time you receive Provenge, you will need to undergo this procedure. Your doctor will give you a schedule for your cell collection and infusion appointments. Contact your doctor right away if you miss an appointment.

  • Provenge is meant to help your immune system work better. Medicines that decrease the function of the immune system, including chemotherapy medicines (eg, cisplatin) or immunosuppressive agents (eg, prednisone), may decrease the effects of Provenge. Tell your doctor if you are taking any of these medicines. Discuss any questions or concerns with your doctor.

  • PREGNANCY and BREAST-FEEDING: It is not known if Provenge can cause harm to the fetus. It is not known if it is found in breast milk. Provenge is not approved for use in women.


Possible side effects of Provenge:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Back pain; fatigue; headache; joint aches; mild pain, fever, or chills; nausea; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); burning, numbness, or tingling; chest pain; confusion; fatigue; fast or irregular heartbeat; fever, chills, or sore throat; muscle spasms or aches; one-sided weakness; redness or pain at the injection site; severe joint aches; severe muscle pain, weakness, or cramping; severe or persistent dizziness, headache, or nausea; shortness of breath; slurred speech; tremors; unusual tiredness or weakness; vision problems; vomiting.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Provenge side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Provenge:

Provenge is usually handled and stored by a health care provider. If you are using Provenge at home, store Provenge as directed by your pharmacist or health care provider. Do not use Provenge if it is past its expiration date. Keep Provenge out of the reach of children and away from pets.


General information:


  • If you have any questions about Provenge, please talk with your doctor, pharmacist, or other health care provider.

  • Provenge is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Provenge. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Provenge resources


  • Provenge Side Effects (in more detail)
  • Provenge Use in Pregnancy & Breastfeeding
  • Provenge Drug Interactions
  • Provenge Support Group
  • 2 Reviews for Provenge - Add your own review/rating


  • Provenge Prescribing Information (FDA)

  • Provenge Advanced Consumer (Micromedex) - Includes Dosage Information

  • Provenge Consumer Overview

  • Sipuleucel-T Professional Patient Advice (Wolters Kluwer)



Compare Provenge with other medications


  • Prostate Cancer

Rafen




Rafen may be available in the countries listed below.


Ingredient matches for Rafen



Ibuprofen

Ibuprofen is reported as an ingredient of Rafen in the following countries:


  • Australia

International Drug Name Search

Pseudoephedrine/Dextromethorphan Chewable Tablets


Pronunciation: sue-do-eh-FED-rin/dex-troe-meth-OR-fan
Generic Name: Pseudoephedrine/Dextromethorphan
Brand Name: PediaCare Long-Acting Cough/Cold


Pseudoephedrine/Dextromethorphan Chewable Tablets are used for:

Relieving congestion and cough due to colds, flu, or hay fever. It may also be used for other conditions as determined by your doctor.


Pseudoephedrine/Dextromethorphan Chewable Tablets are a decongestant and cough suppressant combination. It works by constricting blood vessels and reducing swelling in the nasal passages, which helps you to breathe more easily. The cough suppressant works in the brain to help decrease the cough reflex.


Do NOT use Pseudoephedrine/Dextromethorphan Chewable Tablets if:


  • you are allergic to any ingredient in Pseudoephedrine/Dextromethorphan Chewable Tablets

  • you have severe high blood pressure, rapid heartbeat, or other severe heart problems (eg, heart blood vessel disease)

  • you have taken furazolidone or a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.



Before using Pseudoephedrine/Dextromethorphan Chewable Tablets:


Some medical conditions may interact with Pseudoephedrine/Dextromethorphan Chewable Tablets. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, plan to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of glaucoma, an enlarged prostate gland or other prostate problems, heart problems, diabetes, high blood pressure, blood vessel problems, adrenal gland problems, an overactive thyroid, seizures, or stroke

  • if you have chronic cough, chronic obstructive pulmonary disease (COPD), or other lung problems (eg, asthma, chronic bronchitis, emphysema), or if your cough produces large amounts of mucus

Some MEDICINES MAY INTERACT with Pseudoephedrine/Dextromethorphan Chewable Tablets. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Beta-blockers (eg, propranolol), COMT inhibitors (eg, tolcapone), furazolidone, indomethacin, MAO inhibitors (eg, phenelzine), or tricyclic antidepressants (eg, amitriptyline) because the risk of side effects from Pseudoephedrine/Dextromethorphan Chewable Tablets may be increased

  • Digoxin or droxidopa because the risk of irregular heartbeat or heart attack may be increased

  • Bromocriptine because the risk of side effects may be increased by Pseudoephedrine/Dextromethorphan Chewable Tablets

  • Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Pseudoephedrine/Dextromethorphan Chewable Tablets

This may not be a complete list of all interactions that may occur. Ask your health care provider if Pseudoephedrine/Dextromethorphan Chewable Tablets may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Pseudoephedrine/Dextromethorphan Chewable Tablets:


Use Pseudoephedrine/Dextromethorphan Chewable Tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Pseudoephedrine/Dextromethorphan Chewable Tablets may be taken with or without food.

  • Chew thoroughly before swallowing.

  • If you miss a dose of Pseudoephedrine/Dextromethorphan Chewable Tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Pseudoephedrine/Dextromethorphan Chewable Tablets.



Important safety information:


  • Pseudoephedrine/Dextromethorphan Chewable Tablets may cause dizziness or drowsiness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Pseudoephedrine/Dextromethorphan Chewable Tablets. Using Pseudoephedrine/Dextromethorphan Chewable Tablets alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.

  • Do not take appetite suppressants while you are taking Pseudoephedrine/Dextromethorphan Chewable Tablets without checking with your doctor.

  • Pseudoephedrine/Dextromethorphan Chewable Tablets contains pseudoephedrine. Before you begin taking any new prescription or nonprescription medicine, read the ingredients to see if it also contains pseudoephedrine. If it does or if you are uncertain, contact your doctor or pharmacist.

  • Do NOT exceed the recommended dose or take Pseudoephedrine/Dextromethorphan Chewable Tablets for longer than prescribed without checking with your doctor.

  • If your symptoms do not improve within 5 to 7 days or if they become worse, check with your doctor.

  • Pseudoephedrine/Dextromethorphan Chewable Tablets may interfere with certain lab test results. Make sure that all of your doctors and lab personnel know that you are taking Pseudoephedrine/Dextromethorphan Chewable Tablets.

  • Before you have any medical or dental treatments, emergency care, or surgery, tell the doctor or dentist that you are using Pseudoephedrine/Dextromethorphan Chewable Tablets.

  • Use Pseudoephedrine/Dextromethorphan Chewable Tablets with caution in the ELDERLY because they may be more sensitive to its effects.

  • Caution is advised when using Pseudoephedrine/Dextromethorphan Chewable Tablets in CHILDREN because they may be more sensitive to its effects.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant while taking Pseudoephedrine/Dextromethorphan Chewable Tablets, discuss with your doctor the benefits and risks of using Pseudoephedrine/Dextromethorphan Chewable Tablets during pregnancy. It is unknown if Pseudoephedrine/Dextromethorphan Chewable Tablets are excreted in breast milk. Do not breast-feed while taking Pseudoephedrine/Dextromethorphan Chewable Tablets.


Possible side effects of Pseudoephedrine/Dextromethorphan Chewable Tablets:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Dizziness; excitability; headache; nausea; nervousness or anxiety; trouble sleeping; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.


Proper storage of Pseudoephedrine/Dextromethorphan Chewable Tablets:

Store Pseudoephedrine/Dextromethorphan Chewable Tablets at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Pseudoephedrine/Dextromethorphan Chewable Tablets out of the reach of children and away from pets.


General information:


  • If you have any questions about Pseudoephedrine/Dextromethorphan Chewable Tablets, please talk with your doctor, pharmacist, or other health care provider.

  • Pseudoephedrine/Dextromethorphan Chewable Tablets are to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Pseudoephedrine/Dextromethorphan Chewable Tablets. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Pseudoephedrine/Dextromethorphan resources


  • Pseudoephedrine/Dextromethorphan Use in Pregnancy & Breastfeeding
  • Pseudoephedrine/Dextromethorphan Drug Interactions
  • Pseudoephedrine/Dextromethorphan Support Group
  • 0 Reviews for Pseudoephedrine/Dextromethorphan - Add your own review/rating


Compare Pseudoephedrine/Dextromethorphan with other medications


  • Cough and Nasal Congestion

Wednesday, October 12, 2016

Klotaren




Klotaren may be available in the countries listed below.


Ingredient matches for Klotaren



Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Klotaren in the following countries:


  • Indonesia

International Drug Name Search